Source published November 10, 2026: Ampa vendor announcement, checked against U.S. Food and Drug Administration 510(k) records for the Ampa One and MeRT systems.

An announced connection, not a finished product Ampa and Wave Neuroscience announced a commercial partnership with the intent to integrate Wave's MeRT software with the Ampa One transcranial magnetic stimulation system. The announcement says clinics using Ampa One would be able to add MeRT after the integration is complete. It does not provide a completion date, compatibility-test results or evidence that the combined configuration is currently available.

What each cleared system does FDA records list Ampa One as a Class II repetitive TMS system for adults with major depressive disorder who did not receive satisfactory improvement from antidepressant medication in the current episode. The system uses an integrated camera and a marked cap to help position its coil.

The FDA record for Wave's MeRT System classifies it as a TMS system for post-traumatic stress disorder. Its software analyzes resting eyes-closed EEG and ECG data to recommend an individualized pulse rate from 8 to 13 hertz for a compatible legally marketed TMS device. The MeRT software supplies treatment parameters; it does not itself generate magnetic stimulation.

Why the distinction matters The two systems have separate FDA clearances. Those decisions support their labeled uses as reviewed by the agency, but they do not by themselves establish that the announced integration is complete, that every combined configuration is covered by existing labeling, or that using the systems together improves outcomes compared with other cleared TMS approaches.

Questions clinicians should ask before adoption Before a clinic treats the integration as available, it should verify the released configuration, compatible hardware and software versions, updated labeling, training, quality-control procedures, EEG and ECG acquisition requirements, data handling, pricing and support. Published evidence will also be needed to understand real-world safety, usability and clinical outcomes for the combined workflow.

Why it is worth following If completed and appropriately validated, the integration could give clinics another way to pair EEG- and ECG-derived parameter recommendations with a portable TMS platform. For now, the accurate description is a planned commercial and technical integration between two separately cleared systems, not a new treatment result or demonstrated advantage.

Disclosure This is coverage of a vendor partnership announcement, not a product endorsement or clinical recommendation. Prepared with AI assistance; the Ampa announcement and FDA records K243319, K251210 and K260402 were checked November 14, 2026. The image is an AI-generated conceptual metaphor for an incomplete integration. It does not depict either company's equipment, software, data or a clinical outcome.